IN2012DN03631A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03631A IN2012DN03631A IN3631DEN2012A IN2012DN03631A IN 2012DN03631 A IN2012DN03631 A IN 2012DN03631A IN 3631DEN2012 A IN3631DEN2012 A IN 3631DEN2012A IN 2012DN03631 A IN2012DN03631 A IN 2012DN03631A
- Authority
- IN
- India
- Prior art keywords
- canines
- eye
- carotenes
- amounts
- maladies
- Prior art date
Links
- 241000282465 Canis Species 0.000 abstract 4
- 150000001746 carotenes Chemical class 0.000 abstract 2
- 235000005473 carotenes Nutrition 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000020564 Eye injury Diseases 0.000 abstract 1
- 201000007737 Retinal degeneration Diseases 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 230000004258 retinal degeneration Effects 0.000 abstract 1
- 230000003997 social interaction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides novel methods for maintaining eye health and ameliorating ophthalmic maladies in canines by administering to the canines an ophthalmic malady ameliorating amount of one or more carotenes. Generally, the carotenes are administered to the canines in amounts of from about 0.1 to about 5000 mg or in amounts of from about 0.1 to about 500 mg per day to ameliorate maladies such as impaired vision, cataracts, cloudy eye, retinal degeneration, eye injury caused by radiation, reducing or preventing a decline of social interaction, promoting overall health and wellness, improving the quality of life, and extending the prime for canines.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28017509P | 2009-10-30 | 2009-10-30 | |
| PCT/US2010/002815 WO2011059474A1 (en) | 2009-10-30 | 2010-10-22 | Methods for maintaining eye health and ameliorating opthalmic maladies in canines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03631A true IN2012DN03631A (en) | 2015-06-26 |
Family
ID=43991896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3631DEN2012 IN2012DN03631A (en) | 2009-10-30 | 2010-10-22 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120270954A1 (en) |
| EP (1) | EP2493293B1 (en) |
| JP (1) | JP6071554B2 (en) |
| CN (1) | CN102686107A (en) |
| AU (1) | AU2010318687B2 (en) |
| BR (1) | BR112012010179A2 (en) |
| CA (1) | CA2778229A1 (en) |
| ES (1) | ES2566652T3 (en) |
| IN (1) | IN2012DN03631A (en) |
| MX (1) | MX2012004777A (en) |
| RU (1) | RU2012122169A (en) |
| WO (1) | WO2011059474A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6026719B2 (en) * | 2010-08-31 | 2016-11-16 | 株式会社ダイセル | Visual function preventive / improving agent |
| WO2013043366A1 (en) * | 2011-09-20 | 2013-03-28 | Nestec S.A. | Methods and compositions for improving visual function and eye health |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2094060C1 (en) * | 1994-03-22 | 1997-10-27 | Уфимский научно-исследовательский институт глазных болезней | Eye ointment |
| NZ527924A (en) * | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
| US20020110604A1 (en) * | 2000-08-11 | 2002-08-15 | Ashni Naturaceuticals, Inc. | Composition exhibiting synergistic antioxidant activity |
| WO2002082093A2 (en) * | 2001-04-02 | 2002-10-17 | Tufts University | Methods to measure lipid antioxidant activity |
| CA2484512C (en) | 2002-05-17 | 2013-04-16 | Othera Pharmaceuticals, Inc. | Treatment of cataracts and other ophthalmic diseases |
| BR0311339A (en) | 2002-05-28 | 2005-03-22 | Altana Pharma Ag | Topically applicable pharmaceutical preparation |
| WO2005087208A2 (en) * | 2004-03-10 | 2005-09-22 | Trustees Of Tufts College | Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene |
| JP2008515778A (en) * | 2004-08-18 | 2008-05-15 | シリオン セラピューティクス， インコーポレイテッド | Combination methods, compositions and therapies for treating ocular conditions with 13-cis-retinyl derivatives |
| WO2006116755A2 (en) * | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
| JP2009538353A (en) * | 2006-06-08 | 2009-11-05 | ザ アイムス カンパニー | Composition for promoting eye health |
| US8158667B2 (en) | 2006-08-21 | 2012-04-17 | Kador Peter F | Topical treatment of cataracts in dogs |
| JPWO2009051223A1 (en) | 2007-10-19 | 2011-03-03 | 株式会社アールテック・ウエノ | Pharmaceutical composition for the treatment of cataract |
| EP2268793A2 (en) * | 2008-02-06 | 2011-01-05 | The Procter & Gamble Company | Compositions methods and kits for enhancing immune response to a respiratory condition |
-
2010
- 2010-10-22 ES ES10830307.4T patent/ES2566652T3/en active Active
- 2010-10-22 CA CA2778229A patent/CA2778229A1/en not_active Abandoned
- 2010-10-22 MX MX2012004777A patent/MX2012004777A/en active IP Right Grant
- 2010-10-22 BR BR112012010179A patent/BR112012010179A2/en not_active Application Discontinuation
- 2010-10-22 RU RU2012122169/13A patent/RU2012122169A/en unknown
- 2010-10-22 WO PCT/US2010/002815 patent/WO2011059474A1/en not_active Ceased
- 2010-10-22 AU AU2010318687A patent/AU2010318687B2/en not_active Ceased
- 2010-10-22 EP EP10830307.4A patent/EP2493293B1/en not_active Not-in-force
- 2010-10-22 CN CN2010800595322A patent/CN102686107A/en active Pending
- 2010-10-22 JP JP2012536786A patent/JP6071554B2/en not_active Expired - Fee Related
- 2010-10-22 IN IN3631DEN2012 patent/IN2012DN03631A/en unknown
- 2010-10-22 US US13/503,953 patent/US20120270954A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010318687A1 (en) | 2012-05-24 |
| EP2493293A4 (en) | 2013-03-20 |
| RU2012122169A (en) | 2013-12-10 |
| JP2013509407A (en) | 2013-03-14 |
| ES2566652T3 (en) | 2016-04-14 |
| WO2011059474A1 (en) | 2011-05-19 |
| US20120270954A1 (en) | 2012-10-25 |
| EP2493293B1 (en) | 2016-03-02 |
| JP6071554B2 (en) | 2017-02-01 |
| AU2010318687B2 (en) | 2016-02-25 |
| MX2012004777A (en) | 2012-06-01 |
| BR112012010179A2 (en) | 2015-09-29 |
| CA2778229A1 (en) | 2011-05-19 |
| CN102686107A (en) | 2012-09-19 |
| EP2493293A1 (en) | 2012-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY151018A (en) | Use of nutritional compositions for preventing disorders | |
| MY176679A (en) | Use of nutritional compositions for preventing disorders | |
| WO2012158910A3 (en) | Compositions and methods for treating retinal diseases | |
| TN2009000241A1 (en) | Nutritional supplement composition for treatment of ocular diseases | |
| PH12013500808A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| WO2010105728A3 (en) | Active retinal implant | |
| PH12022550598A1 (en) | Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders | |
| PL2262476T3 (en) | Drug delivery to the anterior and posterior segments of the eye using eye drops. | |
| MX2011013060A (en) | Ophthalmic formulations, methods of manufacture, and methods of using same. | |
| CL2008003120A1 (en) | Compounds derived from phenylalkyl-, phenylalkenyl-, phenylalkynyl amine, phenylthioalkylamine, phenylaminoalkylamine, phenylalkoxyamine and phenylalkylguanidine; pharmaceutical composition; and use of the compounds to treat an ophthalmological disorder or disease such as retinopathy, maculopathy, retinitis pigmentosa, uveitis, among others. | |
| MY160052A (en) | Alkoxy compounds for disease treatment | |
| MX351600B (en) | Antibodies specific for tgf-beta. | |
| WO2007135426A3 (en) | Treatment of neurodegeneratives diseases | |
| TW200744574A (en) | Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement of medicament for ophthalmic use in the form of eye-drops | |
| ATE508711T1 (en) | PRE-FORMED INTRASTROMAL CORNEA INSERT FOR CORNEA ANOMALIES OR DYSTROPHIES | |
| MX347263B (en) | Methods for increasing the production or activity of catalase. | |
| MX2010005205A (en) | Active soluble post-translationally modified neuregulin isoforms. | |
| IN2012DN03631A (en) | ||
| MX2007010752A (en) | Ophthalmic uses of s1p receptor modulators. | |
| WO2010101301A9 (en) | Prophylaxis and treatment of macular degeneration and retinopathy using a prdx protein | |
| WO2013130672A3 (en) | Improved cancer treatments and diagnostics | |
| Poyurovsky | Clozapine in treatment-refractory obsessive-compulsive disorder with comorbid schizotypal personality disorder | |
| Clarke | Non-arteritic anterior ischaemic optic neuropathy: case report | |
| De Rojas | Bilateral choroidal effusion: case report | |
| DE60332122D1 (en) | GENE THERAPY OF THE EYE |